T cell exhaustion represents a critical hurdle in immunology and cancer therapy. Functionally impaired exhausted T cells lose their proliferative capacity and cytotoxic functions, leading to chronic infections or tumor persistence. The process governing this decline has perplexed researchers for years, with efforts to rejuvenate T cells forming the cornerstone of innovative immunotherapies such as checkpoint inhibitors and adoptive T cell transfer.

A groundbreaking study from Professor Ananda Goldrath’s laboratory at the University of California San Diego sheds new light on the molecular underpinnings of T cell exhaustion by delving into the realm of protein homeostasis, or proteostasis. Proteostasis encompasses the complex network responsible for protein synthesis, folding, trafficking, and degradation, ensuring cellular proteins maintain their functional integrity and balance.

Healthy cells continually recycle old or damaged proteins to optimize energy use and renew cellular components—a process paramount to cellular health. This recycling is orchestrated by a constellation of pathways, including ubiquitination, which tags defective proteins for degradation. Disruptions in this delicate equilibrium can lead to protein accumulation, cellular stress, and eventual dysfunction, phenomena well-documented in neurodegenerative disorders but now implicated in immune cell malfunction.

The pivotal discovery from Goldrath’s team reveals that exhausted T cells suffer from impaired proteostasis, particularly in their ability to tag and recycle misfolded proteins efficiently. Using sophisticated mass spectrometry techniques, the researchers identified a significant downregulation of several E3 ubiquitin ligases, enzymes responsible for labeling proteins destined for degradation. Among these, NEURL3, RNF149, and WSB1 emerged as critical players whose diminished activity correlates with protein accumulation and T cell dysfunction.

Nicole Scharping, the lead postdoctoral fellow on the project, explains that the absence of these ubiquitin ligases results in a pathological buildup of damaged proteins within exhausted T cells, akin to a malfunctioning cellular recycling center clogged with refuse. This proteostatic collapse contributes to the loss of T cell vigor, impairing their ability to sustain anti-tumor responses.

Remarkably, the study demonstrated that reintroducing or restoring the expression of these E3 ligases rejuvenated the exhausted T cells. Protein aggregates diminished, normal proteostasis was reinstated, and the T cells regained their capacity to proliferate and execute powerful tumor cell clearance. These findings suggest that maintaining or rescuing proteostasis could be harnessed as a therapeutic avenue to counteract T cell exhaustion in cancer treatment.

This insight has profound implications, particularly for cancer immunotherapy. The efficacy of treatments such as CAR T-cell therapies or immune checkpoint blockers often hinges on the functionality of T cells within the tumor microenvironment. By preventing or reversing proteostatic disruption, clinicians may enhance the durability of T cell responses, potentially overcoming resistance and relapse in aggressive cancers.

The parallels drawn between T cell exhaustion and protein aggregation diseases such as Parkinson’s and Alzheimer’s are striking. Both scenarios involve a failure of cellular quality control machinery leading to pathogenic protein accumulation. This convergence highlights a broader biological principle whereby proteostasis governs cell fate across diverse physiological systems and diseases.

The comprehensive use of mass spectrometry was vital to unraveling this mechanism. Collaborations with Professor Eric Bennett’s lab at UC San Diego and the Global Autoimmune Institute under Assistant Professor Samuel Myers enabled high-resolution protein profiling, revealing the extensive landscape of ubiquitination alterations in exhausted T cells. This approach not only pinpointed key ligases but opened doors for identifying additional proteostatic regulators in immune dysfunction.

While these discoveries were obtained in mouse models, the translational potential is promising. The molecular machinery of proteostasis is highly conserved, suggesting that similar therapeutic interventions could be developed for human immunotherapy. Targeted modulation of E3 ligases or proteostasis pathways could synergize with existing treatments to reinvigorate T cells battling chronic infections and cancers.

Professor Goldrath emphasizes the therapeutic horizon this research unveils: “Understanding how to restore the protein recycling system in T cells gives us a novel target to boost immune function. This can revolutionize immunotherapy strategies, improving patient outcomes not just in cancer but potentially in chronic infectious diseases.”

By shifting the paradigm from solely focusing on inhibitory receptors or metabolic exhaustion to addressing fundamental cellular quality control deficits, this study pioneers a new frontier in our understanding of T cell biology. It invites scientists and clinicians alike to explore drug development targeting proteostasis, heralding a new wave of immune modulation technologies.

As the global scientific community races to decode the complexities of immune exhaustion, this work represents a critical milestone. It reaffirms the importance of interdisciplinary approaches combining immunology, cell biology, and advanced proteomics to tackle intractable health challenges. Ultimately, it lays the groundwork for transforming T cell exhaustion from a formidable barrier into a manageable therapeutic target.

Subject of Research: Animals
Article Title: Proteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte function
News Publication Date: 29-Apr-2026
Web References: http://dx.doi.org/10.1016/j.cell.2026.02.019
Image Credits: Yun Hsuan Elena Lin
Keywords: T cell activation, Immune response, Proteostasis, Tumor cells, Immunology, Immunotherapy, Cancer

Unlike well-characterized checkpoints such as PD-1 and CTLA-4 that require engagement with tumor or stromal cells to dampen T cell activity, SLAMF6 functions autonomously on the T cell surface. Dr. Veillette’s team elucidated that SLAMF6 self-activates, transmitting inhibitory signals independent of tumor cell interaction. This mechanism intrinsically limits T cell effector functions by not only weakening the cytotoxic attack capacity but also by impairing the generation of durable, resilient T cell populations capable of sustained tumor control.

Moreover, SLAMF6 signaling accelerates the progression toward T cell exhaustion, a dysfunctional state marked by diminished cytokine production, proliferative capacity, and cytolytic activity. This state poses a major obstacle in cancer immunotherapy, as exhausted T cells fail to eradicate malignant cells effectively. By uncovering this internal immune brake, the discovery offers crucial insight into why many patients show limited or transient responses to current checkpoint inhibitors like PD-1/PD-L1 blockers.

Capitalizing on this insight, the researchers engineered monoclonal antibodies designed to disrupt SLAMF6 homotypic interactions on T cells. These novel biologics demonstrated impressive preclinical efficacy, leading to a marked increase in T cell activation and proliferation. In murine tumor models, treatment with SLAMF6-neutralizing antibodies resulted in enhanced infiltration of functional T cells, reduced immune exhaustion markers, and potent suppression of tumor growth. These effects collectively surpass the efficacy of previously available SLAMF6 targeting agents.

The implications of this research are profound. By neutralizing an internally driven suppressive pathway, these antibodies represent a next-generation immunotherapeutic strategy that may complement or even supersede established checkpoint inhibitors. Importantly, they offer hope to patients who have developed resistance or exhibited non-responsiveness to PD-1/PD-L1 therapies, a population in urgent need of novel treatment options.

Dr. Veillette emphasizes that the unique properties of SLAMF6 inhibition could enable combination therapies that synergize with other immune modulators, potentially enhancing anti-tumor immunity beyond current limits. The research team plans to advance these promising antibodies into early-phase clinical trials to rigorously assess their safety profile and therapeutic efficacy in diverse cancer types, including both solid tumors and hematological malignancies.

This innovative approach to cancer immunotherapy epitomizes a paradigm shift from exclusively targeting tumor-induced immune suppression toward addressing intrinsic immune regulatory checkpoints. The work underscores the critical importance of translational research in bridging fundamental immunology with clinical oncology, accelerating the development of precision medicines that tailor treatments to the complex biology of both tumors and immune cells.

The research was supported by leading Canadian funding bodies including the Canadian Institutes of Health Research (CIHR), the Terry Fox Research Institute, and the Canadian Foundation for Innovation, reflecting robust national commitment to advancing cancer treatment landscapes. The IRCM, renowned for its pioneering molecular oncology research, continues to lead in elucidating the mechanisms resistance to immunotherapy and developing innovative solutions to overcome these challenges.

IRCM’s president, Dr. Jean-François Côté, heralded this discovery as a “new chapter in immunotherapy,” highlighting the unprecedented ability to unmask and neutralize a heretofore hidden immune checkpoint. This breakthrough not only enhances our molecular understanding of T cell regulation but also carries tangible potential to transform patient care worldwide, addressing the stubborn limitations of current immunotherapeutic regimens.

In summary, SLAMF6 represents a novel, druggable target that intrinsically suppresses T cell immunity in cancer. The development of potent SLAMF6-blocking antibodies that restore T cell vigor and counter exhaustion sets the stage for a promising new frontline in cancer immunotherapy. With ongoing clinical evaluation anticipated, this discovery heralds a new generation of treatments aimed at harnessing the full power of the immune system to eradicate cancer.

Subject of Research: Animals
Article Title: SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer
News Publication Date: 11-Feb-2026
Web References: https://www.nature.com/articles/s41586-026-10106-5
References: Veillette, A., et al. “SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer.” Nature, Feb 11, 2026. DOI: 10.1038/s41586-026-10106-5
Keywords: Tumor cells, Antibody therapy, Cancer immunotherapy, T cell exhaustion, Immune checkpoint, SLAMF6, Monoclonal antibodies